Matinas BioPharma Holdings (MTNB) Accounts Payables (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Accounts Payables of $712000.0 for Q1 2026, up 152.48% year-over-year from $282000.0 in Q1 2025, and up 126.03% quarter-over-quarter from $315000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Accounts Payables (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Accounts Payables for 14 consecutive years, with $712000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 152.48% year-over-year to $712000.0; the TTM figure through Mar 2026 stood at $712000.0 (up 152.48% YoY), while the FY2025 annual figure was $315000.0, up 231.58% from the prior year.
- Accounts Payables improved to $712000.0 in Q1 2026 per MTNB's latest filing, from $315000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $1.4 million in Q1 2022 and bottomed at $80000.0 in Q3 2025.
- Historically, Accounts Payables has averaged $488457.2 across 5 years, with a median of $497151.0 in 2022.
- Annual changes were most pronounced in 2024 — Accounts Payables slumped 81.52% — and 2025, when it soared 231.58%.
- Matinas BioPharma Holdings' Accounts Payables stood at $618000.0 in 2022, then fell by 16.83% to $514000.0 in 2023, then plunged by 81.52% to $95000.0 in 2024, then jumped by 231.58% to $315000.0 in 2025, then jumped by 126.03% to $712000.0 in 2026.
- Business Quant data shows MTNB's Accounts Payables at $712000.0 in Q1 2026, $315000.0 in Q4 2025, and $80000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | 845,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 845,000.00 |
| Mar 31, 2026 | 712,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 167,000.00 |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | 95,000.00 |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | 238,000.00 |
| Mar 31, 2024 | 473,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Sep 30, 2023 | 835,000.00 |
| Jun 30, 2023 | 604,000.00 |
| Mar 31, 2023 | 516,000.00 |
| Dec 31, 2022 | 618,000.00 |
| Sep 30, 2022 | 656,717.00 |
| Jun 30, 2022 | 497,151.00 |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 937,000.00 |
| Sep 30, 2021 | 661,998.00 |